Skip to main content Back to Top
Advertisement

11/6/2024

Lenalidomide Capsules

Products Affected - Description

    • Lenalidomide oral capsule, Alvogen, 10 mg, bottle, 100 count, NDC 47811-0485-01
    • Lenalidomide oral capsule, Alvogen, 15 mg, bottle, 100 count, NDC 47811-0486-01
    • Lenalidomide oral capsule, Alvogen, 20 mg, bottle, 21 count, NDC 47811-0487-77
    • Lenalidomide oral capsule, Alvogen, 25 mg, bottle, 100 count, NDC 47811-0488-01
    • Lenalidomide oral capsule, Alvogen, 5 mg, bottle, 100 count, NDC 47811-0484-01
    • Lenalidomide oral capsule, Apotex, 10 mg, bottle, 28 count, NDC 60505-4534-02
    • Lenalidomide oral capsule, Apotex, 15 mg, bottle, 21 count, NDC 60505-4535-02
    • Lenalidomide oral capsule, Apotex, 2.5 mg, bottle, 28 count, NDC 60505-4532-02
    • Lenalidomide oral capsule, Apotex, 20 mg, bottle, 21 count, NDC 60505-4536-02
    • Lenalidomide oral capsule, Apotex, 25 mg, bottle, 21 count, NDC 60505-4537-02
    • Lenalidomide oral capsule, Apotex, 5 mg, bottle, 28 count, NDC 60505-4533-02
    • Lenalidomide oral capsule, Camber, 10 mg, bottle, 28 count, NDC 31722-0259-28
    • Lenalidomide oral capsule, Camber, 15 mg, bottle, 21 count, NDC 31722-0260-21
    • Lenalidomide oral capsule, Camber, 2.5 mg, bottle, 28 count, NDC 31722-0257-28
    • Lenalidomide oral capsule, Camber, 20 mg, bottle, 21 count, NDC 31722-0261-21
    • Lenalidomide oral capsule, Camber, 25 mg, bottle, 21 count, NDC 31722-0262-21
    • Lenalidomide oral capsule, Camber, 5 mg, bottle, 28 count, NDC 31722-0258-28
    • Lenalidomide oral capsule, Cipla USA, 2.5 mg, bottle, 28 count, NDC 69097-0604-73

Reason for the Shortage

    • Generic lenalidomide capsules have volume restrictions as part of the patent settlements between generic companies and Celgene (Bristol Myers Squibb). The volume restrictions are expected to be in effect until January 31, 2026.
    • Alvogen did not provide a reason for the shortage.
    • Apotex did not provide a reason for the shortage.
    • Bristol Myers Squibb has Revlimid available.
    • Camber allocates specific amounts to REMS certified specialty pharmacies due to the volume restrictions for lenalidomide.
    • Cipla did not provide a reason for the shortage.
    • Dr. Reddy's was not available to provide information.
    • Mylan has lenalidomide capsules available.
    • Sun has lenalidomide capsules available.
    • Teva has lenalidomide capsules available.

Available Products

    • Revlimid oral capsule, Bristol-Myers Squibb, 10 mg, bottle, 28 count, NDC 59572-0410-28
    • Revlimid oral capsule, Bristol-Myers Squibb, 10 mg, bottle, 100 count, NDC 59572-0410-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 15 mg, bottle, 21 count, NDC 59572-0415-21
    • Revlimid oral capsule, Bristol-Myers Squibb, 15 mg, bottle, 100 count, NDC 59572-0415-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 2.5 mg, bottle, 28 count, NDC 59572-0402-28
    • Revlimid oral capsule, Bristol-Myers Squibb, 2.5 mg, bottle, 100 count, NDC 59572-0402-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 20 mg, bottle, 21 count, NDC 59572-0420-21
    • Revlimid oral capsule, Bristol-Myers Squibb, 20 mg, bottle, 100 count, NDC 59572-0420-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 25 mg, bottle, 21 count, NDC 59572-0425-21
    • Revlimid oral capsule, Bristol-Myers Squibb, 25 mg, bottle, 100 count, NDC 59572-0425-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 5 mg, bottle, 28 count, NDC 59572-0405-28
    • Revlimid oral capsule, Bristol-Myers Squibb, 5 mg, bottle, 100 count, NDC 59572-0405-00
    • Lenalidomide oral capsule, Alvogen, 10 mg, bottle, 28 count, NDC 47811-0485-28
    • Lenalidomide oral capsule, Alvogen, 15 mg, bottle, 21 count, NDC 47811-0486-77
    • Lenalidomide oral capsule, Alvogen, 2.5 mg, bottle, 28 count, NDC 47811-0483-28
    • Lenalidomide oral capsule, Alvogen, 25 mg, bottle, 21 count, NDC 47811-0488-77
    • Lenalidomide oral capsule, Alvogen, 5 mg, bottle, 28 count, NDC 47811-0484-28
    • Lenalidomide oral capsule, Cipla USA, 10 mg, bottle, 28 count, NDC 69097-0382-73
    • Lenalidomide oral capsule, Cipla USA, 15 mg, bottle, 21 count, NDC 69097-0383-81
    • Lenalidomide oral capsule, Cipla USA, 20 mg, bottle, 21 count, NDC 69097-0384-81
    • Lenalidomide oral capsule, Cipla USA, 25 mg, bottle, 21 count, NDC 69097-0385-81
    • Lenalidomide oral capsule, Cipla USA, 5 mg, bottle, 28 count, NDC 69097-0381-73
    • Lenalidomide oral capsule, Mylan (Viatris), 10 mg, bottle, 28 count, NDC 00378-1937-28
    • Lenalidomide oral capsule, Mylan (Viatris), 10 mg, bottle, 100 count, NDC 00378-1937-01
    • Lenalidomide oral capsule, Mylan (Viatris), 15 mg, bottle, 21 count, NDC 00378-1941-21
    • Lenalidomide oral capsule, Mylan (Viatris), 15 mg, bottle, 100 count, NDC 00378-1941-01
    • Lenalidomide oral capsule, Mylan (Viatris), 2.5 mg, bottle, 28 count, NDC 00378-1935-28
    • Lenalidomide oral capsule, Mylan (Viatris), 2.5 mg, bottle, 100 count, NDC 00378-1935-01
    • Lenalidomide oral capsule, Mylan (Viatris), 20 mg, bottle, 21 count, NDC 00378-1942-21
    • Lenalidomide oral capsule, Mylan (Viatris), 20 mg, bottle, 100 count, NDC 00378-1942-01
    • Lenalidomide oral capsule, Mylan (Viatris), 25 mg, bottle, 21 count, NDC 00378-1940-21
    • Lenalidomide oral capsule, Mylan (Viatris), 25 mg, bottle, 100 count, NDC 00378-1940-01
    • Lenalidomide oral capsule, Mylan (Viatris), 5 mg, bottle, 28 count, NDC 00378-1936-28
    • Lenalidomide oral capsule, Mylan (Viatris), 5 mg, bottle, 100 count, NDC 00378-1936-01
    • Lenalidomide oral capsule, Sun Pharma, 10 mg, bottle, 28 count, NDC 63304-0043-27
    • Lenalidomide oral capsule, Sun Pharma, 15 mg, bottle, 21 count, NDC 63304-0044-22
    • Lenalidomide oral capsule, Sun Pharma, 2.5 mg, bottle, 28 count, NDC 63304-0041-27
    • Lenalidomide oral capsule, Sun Pharma, 20 mg, bottle, 21 count, NDC 63304-0045-22
    • Lenalidomide oral capsule, Sun Pharma, 25 mg, bottle, 21 count, NDC 63304-0046-22
    • Lenalidomide oral capsule, Sun Pharma, 5 mg, bottle, 28 count, NDC 63304-0042-27
    • Lenalidomide oral capsule, Teva, 10 mg, bottle, 28 count, NDC 00480-1243-28
    • Lenalidomide oral capsule, Teva, 15 mg, bottle, 21 count, NDC 00480-1244-21
    • Lenalidomide oral capsule, Teva, 2.5 mg, bottle, 28 count, NDC 00480-1241-28
    • Lenalidomide oral capsule, Teva, 20 mg, bottle, 21 count, NDC 00480-1245-21
    • Lenalidomide oral capsule, Teva, 25 mg, bottle, 21 count, NDC 00480-1246-21
    • Lenalidomide oral capsule, Teva, 5 mg, bottle, 28 count, NDC 00480-1242-28

Estimated Resupply Dates

    • Alvogen has 20 mg capsules in 21 count bottles and all 100 count bottles on back order and the company cannot estimate a release date.
    • Apotex has lenalidomide capsules on back order and the company cannot estimate a release date.
    • Camber allocates specific amounts to REMS certified specialty pharmacies due to the volume restrictions for lenalidomide.
    • Cipla has lenalidomide 2.5 mg capsules available with short expiration dating.

Updated

Updated November 6, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 11, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT